Certara has announced a partnership with NVIDIA to enhance its AI platform for drug discovery and development by incorporating the NVIDIA BioNeMo Agent Toolkit. This collaboration aims to unify Certara's biosimulation software, regulatory expertise, and datasets with AI-driven agents that provide specialized insights for life sciences. The toolkit enables AI agents to function autonomously, complementing biosimulation models and scientific expertise to accelerate the drug development process. This approach promises to improve insight generation throughout the development continuum by computationally simulating human biology, potentially transforming how new medicines are discovered and developed.

• NVIDIA (NasdaqGS:NVDA) last closed at $196.93 up 0.7%.

In other market news, Skyverse Technology (SHSE:688361) was trading firmly up 14.4% and ending the day at CN¥408.00. At the same time, Astera Labs (NasdaqGS:ALAB) lagged, down 11.5% to end trading at $382.89.

Best AI Chip Stocks

• Broadcom (NasdaqGS:AVGO) settled at $370.78 down 0.8%. On Monday, Broadcom announced an expanded collaboration with Apple to develop and supply custom ASIC silicon products through 2031.
• Micron Technology (NasdaqGS:MU) finished trading at $938.38 down 4.7%. Two days ago, Micron formed a long-term strategic agreement with Ford to enhance the supply of memory solutions for next-gen vehicles.
• Advanced Micro Devices (NasdaqGS:AMD) ended the day at $516.11 down 6.5%.

Taking Advantage

• Click here to unveil our expertly curated list of 138 AI Chip Stocks including Cambricon Technologies, Moore Threads Technology and Hygon Information Technology.
• Want Some Alternatives? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Sources: